These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15076221)

  • 1. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients.
    Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H; Suzuki H
    J Cardiovasc Pharmacol; 2004 Mar; 43(3):380-6. PubMed ID: 15076221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
    Shibasaki Y; Masaki H; Nishiue T; Nishikawa M; Matsubara H; Iwasaka T
    Nephron; 2002 Mar; 90(3):256-61. PubMed ID: 11867945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
    Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Losartan controlled blood pressure and reduced left ventricular hypertrophy but did not alter arrhythmias in hypertensive men with preserved systolic function.
    Zakynthinos E; Pierrutsakos Ch; Daniil Z; Papadogiannis D
    Angiology; 2005; 56(4):439-49. PubMed ID: 16079926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction in hypertensives, but does not affect diastolic cardiac function.
    Zakynthinos E; Pierutsakos Ch; Konstantinidis K; Zakynthinos S; Papadogiannis D
    Angiology; 2004; 55(6):669-78. PubMed ID: 15547653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
    Boner G; Cooper ME; McCarroll K; Brenner BM; de Zeeuw D; Kowey PR; Shahinfar S; Dickson T; Crow RS; Parving HH;
    Diabetologia; 2005 Oct; 48(10):1980-7. PubMed ID: 16082528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B; Gleim G; Panish J
    Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients.
    Klingbeil AU; Müller HJ; Delles C; Fleischmann E; Schmieder RE
    Am J Hypertens; 2000 Dec; 13(12):1295-300. PubMed ID: 11130774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis.
    Mitsuhashi H; Tamura K; Yamauchi J; Ozawa M; Yanagi M; Dejima T; Wakui H; Masuda S; Azuma K; Kanaoka T; Ohsawa M; Maeda A; Tsurumi-Ikeya Y; Okano Y; Ishigami T; Toya Y; Tokita Y; Ohnishi T; Umemura S
    Atherosclerosis; 2009 Nov; 207(1):186-90. PubMed ID: 19423110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
    Shibasaki Y; Nishiue T; Masaki H; Matsubara H; Iwasaka T
    Nihon Rinsho; 2002 Oct; 60(10):1992-8. PubMed ID: 12397697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy.
    Nielsen FS; Ali S; Rossing P; Bang LE; Svendsen TL; Gall MA; Smidt UM; Kastrup J; Parving HH
    Diabet Med; 1997 Jul; 14(7):538-46. PubMed ID: 9223391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal control of blood pressure can reverse left ventricular hypertrophy in uremic hypertensive hemodialysis patients.
    Wu SG; Lin SL; Wu CM; Jeng FR; Su CZ
    Kaohsiung J Med Sci; 1999 Feb; 15(2):62-8. PubMed ID: 10089714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate.
    Li H; Wang SX
    J Nephrol; 2011; 24(2):236-45. PubMed ID: 21240870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
    Suzuki H; Kanno Y; Ikeda N; Nakamoto H; Okada H; Sugahara S
    Hypertens Res; 2002 Nov; 25(6):865-73. PubMed ID: 12484510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.